Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | PRKDC | P78527 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991013 | 0.91 | PIK3CA (0.72) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL12535633 | 0.83 | PIK3CA (0.84) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL989069 | 0.83 | PIK3CA (0.86) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL12555280 | 0.83 | PIK3CA (0.81) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL12535893 | 0.83 | PIK3CA (0.69) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL989302 | 0.82 | PIK3CA (0.69) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL12316876 | 0.82 | PIK3CA (0.86) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL989478 | 0.80 | PIK3CA (0.86) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL988062 | 0.80 | PIK3CA (0.63) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL989466 | 0.77 | PIK3CA (0.82) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247567-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247567-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | PIK3CA 1/4885PIK3CB 9/4885PIK3CD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.